UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 18, 2017

 

 

Myovant Sciences Ltd.

(Exact name of registrant as specified in its charter)

 

 

 

Bermuda   001-37929   98-1343578

(State or other jurisdiction

of incorporation)

  (Commission File No.)   (I.R.S. Employer Identification No.)

Suite 1, 3 rd Floor

11-12 St. James’s Square

London SW1Y 4LB

United Kingdom

  Not Applicable
(Address of principal executive office)   (Zip Code)

Registrant’s telephone number, including area code: +44 203 318 9709

 

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☒

 

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

On August 18, 2017, Myovant Sciences Ltd. (the “Company”) held its 2017 Annual General Meeting of Shareholders (the “Annual Meeting”) in London, United Kingdom. At the Annual Meeting, the shareholders considered and approved two proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on July 21, 2017. Set forth below is a brief description of each matter voted upon and the results with respect to each such matter.

Proposal No. 1 : Mark Altmeyer, Terrie Curran, and Keith Manchester, M.D., were elected to serve as Class I Directors to serve until the Company’s 2020 Annual General Meeting of Shareholders and until their successors are duly elected, by the following votes:

 

Name

   Votes For      Votes Against      Abstain      Broker Non-Votes  

Mark Altmeyer

     55,047,228        1,209,235        420        388,539  

Terrie Curran

     56,256,333        100        450        388,539  

Keith Manchester, M.D.

     54,616,885        1,639,578        420        388,539  

 

Proposal No. 2 : The shareholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending March 31, 2018, the appointment of Ernst & Young LLP as the Company’s auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for the Company’s fiscal year ending March 31, 2018 and the authorization of the Company’s Board of Directors, through the Audit Committee, to set the remuneration for Ernst & Young LLP as the Company’s auditor for the Company’s fiscal year ending March 31, 2018, by the following votes:

 

 

     Votes For      Votes Against      Abstain      Broker Non-Votes  
     56,644,965        50        407        0  


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

        Myovant Sciences Ltd.

Date: August 23, 2017

    By:   /s/ Frank Karbe
     

 

      Name:   Frank Karbe
      Title:   Principal Financial and Accounting Officer
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Myovant Sciences Charts.
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Myovant Sciences Charts.